Stanford Blood Center Becomes Second Blood Center to Provide FDA-Licensed High-Titer COVID-19 Convalescent Plasma

Stanford Blood Center (SBC), an AABB institutional member, recently became the country’s second blood center to receive Food and Drug Administration approval to provide licensed high-titer COVID-19 convalescent plasma (CCP) to treat individuals who are immunocompromised and unable to make their own antibodies to the virus. The new approval grants SBC the ability to collect and manufacture CCP at its locations and distribute the product to hospitals and blood centers in California and beyond.

SBC was one of the first U.S. blood centers to begin collecting CCP early in the COVID-19 pandemic and has played a key role in research and patient care efforts to evaluate and optimize its use.

“This FDA approval reaffirms our commitment to providing patients with what they need, when they need it, a core value of our organization,” said Harpreet Sandhu, Stanford Blood Center’s CEO. “By securing licensure, we are able to continue supporting immunocompromised patients across the nation who can benefit from convalescent plasma therapy.”